0001358403-15-000038.txt : 20150706
0001358403-15-000038.hdr.sgml : 20150703
20150706165921
ACCESSION NUMBER: 0001358403-15-000038
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150701
FILED AS OF DATE: 20150706
DATE AS OF CHANGE: 20150706
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC
CENTRAL INDEX KEY: 0001358403
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 201450200
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2130 WEST HOLCOMBE BOULEVARD
STREET 2: SUITE 800
CITY: HOUSTON
STATE: TX
ZIP: 77030
BUSINESS PHONE: (832) 384-1100
MAIL ADDRESS:
STREET 1: 2130 WEST HOLCOMBE BOULEVARD
STREET 2: SUITE 800
CITY: HOUSTON
STATE: TX
ZIP: 77030
FORMER COMPANY:
FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moseley Annemarie
CENTRAL INDEX KEY: 0001626892
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36783
FILM NUMBER: 15974098
MAIL ADDRESS:
STREET 1: C/O BELLICUM PHARMACEUTICALS, INC.
STREET 2: 2130 W. HOLCOMBE BLVD., STE. 800
CITY: HOUSTON
STATE: TX
ZIP: 77030
4
1
wf-form4_143621635139106.xml
FORM 4
X0306
4
2015-07-01
0
0001358403
BELLICUM PHARMACEUTICALS, INC
BLCM
0001626892
Moseley Annemarie
C/O BELLICUM PHARMACEUTICALS, INC.
2130 W. HOLCOMBE BLVD., STE. 800
HOUSTON
TX
77030
0
1
0
0
COO/EVP Clinical Development
Common Stock
2015-07-01
4
M
0
35000
2.55
A
35122
D
Common Stock
2015-07-01
4
S
0
33950
20.5959
D
1172
D
Common Stock
2015-07-01
4
S
0
1050
21.3253
D
122
D
Stock Option (right to buy)
2.55
2015-07-01
4
M
0
35000
0
D
2021-11-08
Common Stock
35000.0
53235
D
Includes 122 shares acquired under the Issuer's Employee Stock Purchase Plan on June 10, 2015.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2015.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.27 to $21.26. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.29 to $21.38. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
25% of the shares subject to the stock option vested and became exercisable on November 9, 2012, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
/s/ Annemarie Moseley, Ph.D., M.D.
2015-07-06